Bloks Group Limited — Governance Information 2007

Mar 19, 2007

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HONG KONG PHARMACEUTICAL HOLDINGS LIMITED 香港葯業集團有限公司[*]

(incorporated in Bermuda with limited liability)

(Stock code: 182)

PROPOSED AMENDMENT TO THE BYE-LAWS

The Board announces that it proposes to amend the existing Bye-law 102(B) subject to the approval of the Shareholders at the AGM. A circular setting out, among other things, the proposed amendment to the Bye-laws will be dispatched to the Shareholders on or around 19 March 2007.

PROPOSED AMENDMENT TO THE BYE-LAWS

Under the existing Bye-law 102(B), all Directors appointed in general meeting of the Company or by the Board from time to time shall hold office only until the next general meeting of the Company after their appointments. The Company does not intend to require Directors appointed in general meeting by ordinary resolution of the Shareholders to retire and subject to re-election in the next general meeting of the Company. The above arrangement is a result of a typographical error in the existing Bye-law 102(B). To rectify the above situation, the Board proposes to amend Bye-law 102(B) so that Directors appointed in general meeting will not be required to retire in the next general meeting of the Company after their appointments. Directors appointed by the Board without Shareholders’ approval will continue to be required to retire, but be eligible for re-election at the next following annual general meeting of the Company after their appointments.

A circular setting out, among other things, the proposed amendment to the Bye-laws will be dispatched to the Shareholders on or around 19 March 2007.

GENERAL

As at the date of this announcement, the Board comprises Mr. Ko Chun Shun, Johnson, Mr. Chan Kam Kwan, Jason, Mr. Tsoi Tong Hoo, Tony, Mr. Wong Fan, Frank, and Mr. Yeung Heung Yeung (who are executive Directors), Mr. Kelvin Edward Flynn (who is a non-executive Director), and Mr. Ho Tak Man, Billy, Dr. Wong Yau Kar, David and Mr. Yap Fat Suan (who are independent non-executive Directors).

— 1 —

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“AGM”

the next annual general meeting to be convened and held by the Company

“Board” the board of the Directors “Bye-laws” the bye-laws of the Company

“Company” Hong Kong Pharmaceutical Holdings Limited, a company incorporated in Bermuda with limited liability, and the Shares of which are listed on the main board of the Stock Exchange

“Directors” directors of the Company

• “Shareholders” holders of the Shares

• “Share(s)” the ordinary share(s) of HK$0.01 each in the share capital of the Company

By order of the Board HONG KONG PHARMACEUTICAL HOLDINGS LIMITED Jason Chan Company Secretary

16 March 2007, Hong Kong

* for identification purposes only

Please also refer to the published version of this announcement in the China Daily.

— 2 —